Supplementary File:Metformin inhibits the progression of prostate cancer by in-ducing purine metabolic alters and enhancing the PDE6D / cGMP / PKG pathway

Name: Supplementary File:Metformin inhibits the progression of prostate cancer by in-ducing purine metabolic alters and enhancing the PDE6D / cGMP / PKG pathway
Creator: , Tang
Keywords: 3. Good health

descriptionPublicationkeyboard_double_arrow_right Article 17 Nov 2022Publisher:Zenodo

Authors: , Tang;

doi: 10.5281/zenodo.7329284 , 10.5281/zenodo.7329283

Supplementary File:Metformin inhibits the progression of prostate cancer by in-ducing purine metabolic alters and enhancing the PDE6D / cGMP / PKG pathway

- Summary
- Metrics

Abstract

Supplementary Materials: Table S1: Significant altered metabolites between the metformin (+) group and metformin (-) group in positive mode.; Table S2: Significant altered metabolites between the metformin (+) group and metformin (-) group in negative mode.; Table S3: Differential expressed genes between the metformin (+) group and metformin (-) group.File S4: Untargeted metabolomic sequencing data.

Related Organizations

First Affiliated Hospital of Guangzhou Medical University
China (People's Republic of)

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	0
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average